Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Julphar
Argus Health
Mallinckrodt
Accenture
US Army
McKesson
Deloitte
Queensland Health
US Department of Justice

Generated: August 21, 2018

DrugPatentWatch Database Preview

LYNPARZA Drug Profile

see a sample report or, see our see our flat-rate plans

« Back to Dashboard

Which patents cover Lynparza, and when can generic versions of Lynparza launch?

Lynparza is a drug marketed by Astrazeneca Pharms and is included in two NDAs. There are eight patents protecting this drug.

This drug has two hundred and sixty-five patent family members in forty-eight countries.

The generic ingredient in LYNPARZA is olaparib. There are three drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the olaparib profile page.

Summary for LYNPARZA
Drug patent expirations by year for LYNPARZA
Generic Entry Opportunity Date for LYNPARZA
Generic Entry Dates for LYNPARZA*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
CAPSULE;ORAL
Generic Entry Dates for LYNPARZA*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
TABLET;ORAL

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Pharmacology for LYNPARZA
Synonyms for LYNPARZA
(2H)-Phthalazinone, 4-((3-((4-(cyclopropylcarbonyl)-1-piperazinyl)carbonyl)-4-fluorophenyl)methyl)-
09L
1-(cyclopropylcarbonyl)-4-[5-[(3,4-dihydro-4-oxo-1
1-(Cyclopropylcarbonyl)-4-[5-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]-2-fluorobenzoyl]piperazine
1(2H)-Phthalazinone, 4-[[3-[[4-(cyclopropylcarbonyl)-1-piperazinyl]carbonyl]-4-fluorophenyl]methyl]-
1021843-02-6
4-((3-{(4-(cyclopropylcarbonyl)piperazin-1-yl)carbonyl}-4-fluorophenyl)methyl)phthalazin-1(2H)-one
4-({3-[(4-cyclopropanecarbonylpiperazin-1-yl)carbonyl]-4-fluorophenyl}methyl)-1,2-dihydrophthalazin-1-one
4-(3-(4-(Cyclopropanecarbonyl)piperazine-1-carbonyl)-4-fluorobenzyl)phthalazin-1(2H)-one
4-(3-{[4-(Cyclopropylcarbonyl)piperazin-1-Yl]carbonyl}-4-Fluorobenzyl)phthalazin-1(2h)-One
4-[(3-{[4-(Cyclopropylcarbonyl)piperazin-1-yl]carbonyl}-4-fluorophenyl)methyl]phthalazin-1(2H)-one
4-[(3-{[4-Cyclopropylcarbonyl)piperazin-4-yl]carbonyl}-4-fluorophenyl)methyl]phtalazin-1(2H)-one
4-[[3-[4-(cyclopropanecarbonyl)piperazine-1-carbonyl]-4-fluoro-phenyl]methyl]-2H-phthalazin-1-one
4-[[3-[4-(Cyclopropanecarbonyl)piperazine-1-carbonyl]-4-fluorophenyl]methyl]-2H-phthalazin-1-one
4-[3-(4-Cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one
4-{[3-(4-cyclopropanecarbonylpiperazine-1-carbonyl)-4-fluorophenyl]methyl}-1,2-dihydrophthalazin-1-one
4CA-0938
763113-22-0
894104-70-2
937799-91-2
A9666
AB0009952
AB1009702
ABP000423
AC-7939
ACN-032229
Acylpiperazine analogue, 47
AJ-101717
AK-40514
AKOS005145764
AN-493
AN-5279
ANW-43329
AOB1085
API0024518
AX8162101
AZ2281
AZD 2281
AZD 2281|||KU 0059436|||KU 59436
AZD-2281
AZD-2281 (Olaparib)
AZD2281
AZD2281,Olaparib, KU-0059436
AZD2281(olaparib)
AZD2281(olaparib)/AZD-2281/KU0059436
BB 0260909
BC245405
BCP9000363
BCPP000360
BDBM27566
BR-40514
BRD-K02113016-001-08-9
BRD-K02113016-001-09-7
cc-16
CHEBI:83766
CHEMBL521686
CS-0075
CTK8B3857
D09730
D0J9HW
DB09074
EN002690
EX-7210
EX-A002
FDLYAMZZIXQODN-UHFFFAOYSA-N
FT-0083489
FT-0651458
GP0126
GTPL7519
HE068402
HE386863
HMS3654G13
HY-10162
I06-2362
J-503540
KS-00000HXY
KU-0059436
KU-59436
KU0059436
KU59436
Lynparza (TN)
MFCD13185161
MLS006010185
MolPort-009-679-395
NCGC00238451-01
NCGC00238451-02
NSC-747856
NSC747856
Olaparib
Olaparib - AZD2281
Olaparib (AZD2281, Ku-0059436)
Olaparib (AZD2281, KU0059436)
Olaparib (AZD2281)
Olaparib (JAN/USAN/INN)
Olaparib [USAN:INN]
OLAPARIB cpd
Olaparib, KU-0059436, AZD2281,KU0059436, AZD2281
Olaparibum
PubChem19148
QC-2660
RL04905
S-3781
S-7836
s1060
SC-65060
SCHEMBL426568
SMR004701291
SS-4573
UNII-WOH1JD9AR8
WOH1JD9AR8
Z-3275
ZINC40430143

US Patents and Regulatory Information for LYNPARZA

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Astrazeneca Pharms LYNPARZA olaparib TABLET;ORAL 208558-002 Aug 17, 2017 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Astrazeneca Pharms LYNPARZA olaparib TABLET;ORAL 208558-002 Aug 17, 2017 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Astrazeneca Pharms LYNPARZA olaparib TABLET;ORAL 208558-002 Aug 17, 2017 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Astrazeneca Pharms LYNPARZA olaparib CAPSULE;ORAL 206162-001 Dec 19, 2014 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Astrazeneca Pharms LYNPARZA olaparib TABLET;ORAL 208558-001 Aug 17, 2017 RX Yes No ➤ Try a Free Trial ➤ Try a Free Trial Y Y ➤ Try a Free Trial
Astrazeneca Pharms LYNPARZA olaparib TABLET;ORAL 208558-001 Aug 17, 2017 RX Yes No ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Astrazeneca Pharms LYNPARZA olaparib TABLET;ORAL 208558-002 Aug 17, 2017 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

see a sample report or, see our see our flat-rate plans

Non-Orange Book US Patents for LYNPARZA

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,351,701 Therapeutic compounds ➤ Try a Free Trial
7,750,006 Phthalazinone derivatives ➤ Try a Free Trial
9,566,276 Phthalazinone derivatives ➤ Try a Free Trial
8,071,579 DNA damage repair inhibitors for the treatment of cancer ➤ Try a Free Trial
7,531,530 Therapeutic compounds ➤ Try a Free Trial
7,692,006 Phthalazinone derivatives ➤ Try a Free Trial
7,662,818 Phthalazinone derivatives ➤ Try a Free Trial
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

see a sample report or, see our see our flat-rate plans

International Patents for LYNPARZA

Supplementary Protection Certificates for LYNPARZA

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
15/016 Ireland ➤ Try a Free Trial PRODUCT NAME: OLAPARIB, AND SALTS AND SOLVATES THEREOF; REGISTRATION NO/DATE: EU/1/14/959/001 20141216
2015016 Lithuania ➤ Try a Free Trial PRODUCT NAME: OLAPARIBUM; REGISTRATION NO/DATE: EU/1/14/959 20141216
C0022 France ➤ Try a Free Trial PRODUCT NAME: OLAPARIB,SELS ET SOLVATES DE CELUI-CI; REGISTRATION NO/DATE: EU 1/14/959 20141218
00726 Netherlands ➤ Try a Free Trial PRODUCT NAME: OLAPARIB, EN ZOUTEN EN; REGISTRATION NO/DATE: EU/1/14/959/001 20141216
/2015 Austria ➤ Try a Free Trial PRODUCT NAME: OLAPARIB UND SALZE UND SOLVATE DAVON; REGISTRATION NO/DATE: EU/1/14/959 20141216
2015016,C1633724 Lithuania ➤ Try a Free Trial PRODUCT NAME: OLAPARIBAS IR JO DRUSKOS IR SOLVATAI; REGISTRATION NO/DATE: EU/1/14/959 20141216
0150012 00136 Estonia ➤ Try a Free Trial PRODUCT NAME: OLAPARIIB;REG NO/DATE: EU/1/14/959 18.12.2014
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

McKesson
Chinese Patent Office
US Army
Queensland Health
Citi
Baxter
US Department of Justice
Johnson and Johnson
Federal Trade Commission

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.